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Abstract
Multiple dysregulated pathways in tumors necessitate targeting multiple oncogenic elements by
combining orthogonal therapeutic moieties like short-interfering RNAs (siRNA) and drug
molecules in order to achieve a synergistic therapeutic effect. In this manuscript, we describe the
synthesis of cyclodextrin-modified dendritic polyamines (DexAMs) and their application as a
multicomponent delivery vehicle for translocating siRNA and anticancer drugs. The presence of β-
cyclodextrins in our DexAMs facilitated complexation and intracellular uptake of hydrophobic
anticancer drugs-Suberoylanilide hydroxamic acid (SAHA) and Erlotinib, whereas the cationic
polyamine backbone allowed for electrostatic interaction with the negatively charged siRNA. The
DexAMs complexes were found to have minimal cytotoxicity over a wide range of concentrations
and were found to efficiently deliver siRNA, thereby silencing the expression of targeted genes.
As a proof-of concept, we demonstrated that upon appropriate modification with targeting ligands,
we were able to simultaneously deliver multiple payloads -siRNA against oncogenic receptor,
EGFRvIII and anti-cancer drugs (SAHA or erlotinib) efficiently and selectively to glioblastoma
cells. Co-delivery of siRNA-EGFRvIII and SAHA/Erlotinib in glioblastoma cells was found to
significantly inhibit cell proliferation and induce apoptosis, as compared to the individual
treatments.
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Introduction
Advances in the field of chemical genetics and molecular cell biology have triggered a surge
in development of genetic manipulation-based therapies for cancer.1, 2 Such genetic
manipulation methods typically rely on either the traditional small-molecule/protein
modalities3 or the newly discovered RNA interference (RNAi)-based modalities4, each
having their own advantages and disadvantages. For example, RNAi therapeutics can
provide attractive solutions to the major shortcomings of the conventional therapeutics,
including difficulty in lead identification and complex synthesis of small organic molecules
and proteins, and potentially can be applicable to all molecular targets for cancer therapy.5
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However, RNAi-based therapeutics, such as small interfering RNA (siRNA) and micro
RNA (miRNA), are inherently antagonistic and their downstream effects (i.e. gene
silencing) are delayed, compared to those of conventional small molecule/protein based
therapeutics.6 Additionally, owing to their short serum half life and poor cellular uptake,
successful clinical application of siRNA requires appropriate chemical modifications and
better delivery vehicles to overcome the numerous cellular barriers.4 On the other hand,
small organic molecules can act as both antagonists and agonists for molecular targets and
their drug effects can be much faster than siRNA with minimal problems during their
intracellular uptake.5 Hence, from a biological perspective, it would be beneficial to
combine the advantages of these therapeutic modalities to potentially enhance their
individual efficacy. For example, it was recently demonstrated that simultaneous delivery of
siRNA against multidrug resistance genes in cancer cells led to the enhanced efficacy of the
co-delivered anticancer drugs.7, 8 These studies show that it would be desirable to target
multiple oncogenic signaling elements using different therapeutic modalities for cooperative
effect, especially considering the molecular heterogeneity of tumors. However, to achieve
this goal, the primary requirement is to develop non cytotoxic co-delivery platforms capable
of efficient translocation of siRNA and small molecules with specificity as well as identify
the right combination of siRNA and small molecules for a cooperative therapeutic effect.
To address the aforementioned need for cooperative chemotherapeutics, herein we describe
the synthesis of a multifunctional delivery platform consisting of a dendritic polyamine
backbone conjugated with β-cyclodextrin (β-CD) moieties [henceforth referred to as
DexAMs] and its application for target-specific co-delivery of two orthogonal
chemotherapeutic molecules (siRNA and anti-cancer drug). We hypothesize that co-delivery
of siRNA and anticancer drugs will have a cooperative therapeutic effect against the target
oncogenic signaling pathway (EGFRvIII-PI3K/AKT), resulting in the selective induction of
apoptosis in brain tumor cells (Scheme 1). Additionally, conjugation of targeting ligands
against receptors overexpressed in brain cancer cells (EGFR), would allow for selective
uptake of our complexes into glioblastoma cells, thereby minimizing toxic side effects on
normal cells.
Additionally, our delivery platform and synthetic methods have several advantages, as
compared to conventional carrier molecules (e.g. polyethyleneimine (PEI) and
polyamidoamine (PAMAM). These include: (i) minimal cytotoxicity and high transfection
efficiency of siRNA/drug-DexAM constructs, (ii) significantly higher yields and purity of
DexAMs and increased aqueous solubility of DexAM constructs, and (iii) capability of
simultaneously delivering nucleic acids, small organic molecules and proteins, thereby
achieving cooperative therapeutic effects.
Materials and Methods
Starting materials, reagents, and solvents were purchased from commercial suppliers
(Sigma-Aldrich, Acros, and Fisher) and used as received unless otherwise noted. All
reactions were conducted in flame dried glassware with magnetic stirring under an
atmosphere of dry nitrogen. Reaction progress was monitored by analytical thin layer
chromatography (TLC) using 250 μm silica gel plates (Dynamic Absorbents F-254).
Visualization was accomplished with UV light and potassium permanganate stain, followed
by heating. Proton nuclear magnetic resonance (1H NMR) spectra were recorded on either a
Varian-300 instrument (300 MHz), Varian-400 instrument (400 MHz) or a Varian 500
instrument (500 MHz). Chemical shifts of the compounds are reported in ppm relative to
tetramethylsilane (TMS) as the internal standard. Data are reported as follows: chemical
shift, integration, multiplicity (s=singlet, d=doublet, t=triplet, q=quartet, br=broad,
m=multiplet), and coupling constants (Hz).
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Quantification of siRNA loading efficiency
The complexes were prepared at various charge ratios by mixing equal volumes of DexAM
with siRNA in PBS. Charge ratios (N/P) were calculated as a ratio of the number of primary
amines in the polymer, determined from 1H NMR spectra, to the number of anionic
phosphate groups in the siRNA. The samples were then incubated at room temperature for
30 minutes to ensure complex formation. The complexes were prepared at a final siRNA
concentration of 0.2 μg of siRNA/100 μL of solution. 100 μL of each complex were
transferred to a 96-well (black-walled, clear-bottom, non-adsorbing) plate (Corning, NY,
USA). A total of 100 μL of diluted PicoGreen dye (1:200 dilution in Tris- EDTA (TE)
buffer) was added to each sample. Fluorescence measurements were made after 10 minutes
of incubation at room temperature using a M200 Pro Multimode Detector (Tecan USA Inc,
NC, USA), at excitation and emission wavelengths of 485 and 535 nm, respectively. All
measurements were corrected for background fluorescence from a solution containing only
buffer and PicoGreen dye.
Particle size and Zeta potential analysis
Dynamic light scattering (DLS) and Zeta Potential analyses were performed using a
Malvern Instruments Zetasizer Nano ZS-90 instrument (Southboro, MA) with
reproducibility being verified by collection and comparison of sequential measurements.
Polymer/siRNA complexes (siRNA concentration = 330 nM) at different polymer
concentrations, were prepared using purified water (resistivity = 18.5 MΩ-cm). DLS
measurements were performed at a 90° scattering angle at 25°C. Z-average sizes of three
sequential measurements were collected and analyzed. Zeta potential measurements were
collected at 25°C, and the Z-average potentials following three sequential measurements
were collected and analyzed.
Cell culture
Cells were cultured in the following growth media: DMEM (Dulbecco's modified Eagle's
medium) with high glucose (Invitrogen), 10% Fetal Bovine Serum (FBS), 1% streptomycin-
penicillin, 1% glutamax (Invitrogen), and selection markers, G418 (100 μg/ml) and
hygromycin B (30 μg/ml) for U87-EGFP and U87-EGFRvIII respectively. PC-12 cells were
cultured in DMEM with 10% horse serum, 5% FBS and 1% Streptomycin-penicillin. For the
knockdown experiment and targeted delivery, passaged cells were prepared to 40-60%
confluency in 24-well plates. For the knockdown experiment, targeted delivery and cell
viability assay, media was exchanged with serum-free basal media (500μl) and siRNA-
DexAM solution (50 μl) was added after 20-30 minutes. After incubation for 12 hours,
media was exchanged with normal media. Fluorescence measurement and cellular assays
were performed after 48-96 hours from the starting point.
Cytotoxicity assays
The percentage of viable cells was determined by MTS assay following standard protocols
described by the manufacturer. All experiments were conducted in triplicate and averaged.
The quantification of polymer-mediated toxicity was done using MTS assay after incubating
the glioblastoma cells in the presence of varying concentrations of only polymer vehicle for
48-96 h. The data is represented as formazan absorbance at 490 nm, considering the control
(untreated) cells as 100% viable.
Quantification of knockdown of EGFP expression (Image J)
Following siRNA treatment, cells were washed with DPBS and fixed with 2-4%
paraformaldehyde solution prior to imaging. For the fluorescence, DIC, and phase contrast
images were obtained using the Zeiss Axio observer inverted epifluorescence microscope.
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Each image was captured with different channels and focus. Images were processed and
overlapped using Image-Pro (Media Cybernetics) and ImageJ (NIH).
Targeted delivery
Highly tumorigenic U87-EGFP cells and low tumorigenic PC-12 cells were cultured in 24-
well plates, at a density of 5 × 104 cells per well. For PC-12 cells, the normal growth media
was DMEM (with high glucose, Invitrogen), 5% horse serum, 10% FBS, 1% Glutamax, and
1% penicillin-streptomycin. For the delivery of EGFR-Ab conjugated DexAM polyplexes,
media was exchanged with serum free DMEM media. The cells were incubated in the Ab-
conjugated polyplex medium for 6-8 h. Fluorescence images were taken after replacing the
serum-free media with regular media.
Apoptosis assay
Cells were harvested by trypsinization and stained using an Annexin V FITC Apoptosis
Detection kit (Roche, Cambridge, MA) according to the manufacturer's protocol. The
stained cells were immediately analyzed by flow cytometry (FACScan; Becton Dickinson,
Franklin Lake, NJ). Early apoptotic cells with exposed phosphatidylserine but intact cell
membranes bound to Annexin V-FITC but excluded propidium iodide. Cells in necrotic or
late apoptotic stages were labeled with both Annexin V-FITC and propidium iodide.
Results and Discussion
Using multistep solution-phase and solid-phase synthesis, we generated a series of highly
water-soluble dendritic polyamine compounds conjugated to one or more β-cyclodextrin (β-
CD), referred to as DexAMs, with higher yield and purity as compared to reported syntheses
(Scheme 2). The first step for synthesizing DexAM involved generating a dendritic
polyamine backbone by Michael addition of tris(2-aminoethyl)amine and methyl acrylate,
followed by amidation of the amino esters generated after Michael addition. The use of
tris(2-amino ethyl)amine as the core initiator yielded higher surface amine groups and hence
more compact dendrimers as compared to the reported synthetic methods (for e.g.
ethylenediamine, ammonia) for PAMAM dendrimers.9 The conjugation of β-cyclodextrin to
the polyamine backbone involved tosylation of β-cyclodextrin, followed by nucleophilic
addition with amine group. Compared to the previously reported protocol10, where tosyl
chloride was used for regioselective tosylation of β-cyclodextrin resulting in very low yields,
we improved the synthetic yield (~ 50%) and purity by using tosylimidazole, instead of tosyl
chloride, under reflux conditions to generate 6-mono-tosylated β-cyclodextrin (See
supporting information). In the final step, polyamine backbone was conjugated to tosylated-
CD via nucleophilic addition to generate cyclodextrin conjugated polyamines resulting in a
25-fold increase in the aqueous solubility of CD (>50 g/100 mL) as compared to that of CD
alone (<1.8 g/100 mL), owing to generation of an aminium salt (See Supporting Information
for the detailed synthesis).
The first component of our delivery vehicle - β-CD - has been extensively used in
pharmaceutical applications to improve solubility of hydrophobic moieties, such as
anticancer drugs.11 Many anticancer drugs are known to have poor aqueous solubility,
thereby necessitating the use of toxic organic solvents like dimethylsulfoxide (DMSO),
which can be detrimental in biological applications.12 The presence of β-CD in our DexAM
moiety and the optimized drug loading would not only prevent the use of such toxic solvents
but also improve the water-solubility of CD- drug complex for the optimal cellular uptake
and drug efficacy. In our study, two hydrophobic anticancer drugs [Erlotinib and
Suberoylanilide hydroxamic acid (SAHA)] were synthesized and loaded into the β-CD
cavity by using our optimized protocols (Figure 2b).13, 14 For instance, by utilizing the pH-
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dependent solubility of erlotinib, we could load drug up to almost 50% of the molar ratio of
β-CD, resulting in a significant increase in its aqueous solubility (178 mg/100 mL).15, 16
Similarly, we complexed SAHA with β-CD under reflux conditions to obtain highly water-
soluble SAHA-CD complexes (solubility -175 mg/100 mL) [See supporting information for
the more detailed synthesis and experimental protocols].17 The second component of our
DexAMs - dendritic polyamine backbone provides a positive surface charge which can
interact electrostatically with the negatively charged nucleic acids, condensing them into
cationic complexes (known as polyplexes), thus facilitating their intracellular uptake and
endosomal escape.18-20 However, these primary/tertiary amines are also responsible for
cytotoxicity by interacting with the cellular components and interfering in the cellular
processes.21 Hence, there is a clear need to develop synthetic chemistry to control the ratio
of electrostatic properties and the size of polymer structures. Our synthetic methods enabled
us to precisely control the number of primary amine head groups from 4 to 48 leading to
four different generations of DexAMs molecules (D1-D4), thereby allowing us to achieve an
optimal balance between cytotoxicity and complexation ability.
We assessed the capability of our four different generations of DexAMs (D1-D4) to
spontaneously form complexes with the negatively charged siRNA using a well-established
dye exclusion assay. As the number of amine groups increased from DexAM-1 (D1, 4
primary amines) to DexAM-4 (D4, 48 primary amines), the amount of free/unbound siRNA
decreased correspondingly at a given DexAM concentration (see Figure S1 in the supporting
information). Since we found that the complexation ability of DexAM-4 is higher than that
of the other generations with minimal cytotoxicity, we proceeded with using DexAM-4 for
the subsequent experiments. Additionally, the hydrodynamic diameters of the resultant
polyplexes could be controlled from 250 to 400 nm with polydispersity index of 0.8-1.0 by
increasing the polymer concentration (see Figure S2a in the supporting information). The
zeta potentials of the resulting polyplexes were in the range of 8-10 mV at pH 7.4 (see
Figure S2b in the supporting information), demonstrating the cationic nature of the
polyplexes. Cytotoxicity of the DexAM molecules was assessed using MTS assay. First we
confirmed the effect of β-CD moiety on cytotoxicity of DexAMs by comparing the
cytotoxicity of the DexAM (containing CD) to that of the DexAM without CD. Our
cytotoxicity assay data clearly shows that the DexAM constructs with CD show significantly
less cytotoxicity as compared to those without CD (Figure 1a). We believe this is due to the
presence of CDs on a polycationic backbone in DexAM, which can potentially reduce non-
specific binding of the DexAM constructs with proteins or cellular structures.20-23 We also
compared the cytotoxicity of our DexAMs with the commercially available transfection
agents, Polyethyleneimine (PEI), Lipofectamine 2000 (LF) and Xtremegene (Xgene) at the
recommended concentrations for transfection, and found that those agents were significantly
more cytotoxic at those concentrations as compared to DexAMs(Figure 1b).
The optimization of gene silencing with our siRNA-DexAM constructs and assessment of
knockdown efficiency were performed by measuring the suppression of enhanced green
fluorescent protein (EGFP) in glioblastoma cell-lines (U87-EGFP), which were genetically
modified to constitutively express EGFP. The decrease of green fluorescence intensity due
to siRNA-mediated EGFP silencing was monitored over a time-period of 48-96h to quantify
the knockdown efficiency of our DexAM/siRNA constructs (see Figure S4 in the supporting
information). Approximately, 70% of the U87-EGFP cells showed no EGFP signal after 96
h of siRNA treatment as compared to the control cells at a polymer concentration of 100 μM
(Figure 1c) with negligible cytotoxicity (~95 % cell viability). In parallel, we compared the
transfection efficiency and the corresponding cytotoxicity of our delivery platform with that
of the commercially available transfection agent (Xtremegene) under the same condition, in
which Xtremegene–based transfection demonstrated similar levels of EGFP knockdown
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(~70% knockdown efficiency), albeit with significant toxicity (~30 % cell viability) (see
Figure S5 in the supporting information).
In addition to efficient translocation of siRNA across the cell membrane with minimal
cytotoxicity, successful therapeutic application of siRNA also requires the siRNA to interact
with the RNAi machinery within a target cell, thereby minimizing off-target effects.24 Brain
tumor cells, particularly glioblastoma cells, are known to present high levels of epidermal
growth factor receptors (EGFRs) on their cell surface, thus making it a specific biomarker
for cell-specific delivery towards brain tumor cells.25 For targeted delivery to glioblastoma
cells, we modified our DexAM-4 with appropriate ratios of EGFR antibodies
(DexAM-4:EGFR-Ab = 1:5) and incubated them in U87 (glioblastoma cell line, target cells)
and other less-tumorigenic PC-12 cells (control cells) which tend to have low levels of
expression of EGFRs. The DexAM-4constructswere also labeled with a fluorescent dye
(Alexa Fluor 594) to monitor their intracellular uptake using fluorescence microscopy. From
our data we could see that EGFR-antibody modified DexAM-4 were selectively translocated
into U87 (target glioblastoma cells) with high efficiency as compared to the PC-12 (control
cells) (Figure 2a).
Having demonstrated the target-specific delivery and efficient gene silencing capability of
the siRNA-DexAM constructs, we then focused on our main goal of co-delivering siRNA
and anticancer drugs for targeting key oncogenic signaling pathways (e.g. EGFRvIII-
(phoshphatidylinositol-3-kinase)PI3K/AKT) to achieve a cooperative chemotherapeutic
effect. Tumors harbor multiple dysregulated signaling pathways, thus limiting the clinical
utility of single target agents.26 Hence, combining approaches targeting multiple oncogenic
elements, using a single delivery platform, can not only increase the likelihood of blocking
tumor survival and metastasis, as compared to individual treatments, but also simplify
clinical applications. For this purpose, we focused on developing a combinatory therapeutic
approach based on siRNA and anticancer cancer drugs targeting oncogenic pathways in
glioblastoma multiforme (GBM), an extremely aggressive and difficult-to-treat form of
primary brain tumor. We aimed at down-regulating the EGFRvIII-PI3K/AKT pathway,
implicated in the proliferation and apoptosis of brain tumor cells, by delivering siRNA
against epidermal growth factor receptor variant III (EGFRvIII), which is known to enhance
the tumorigenicity of GBM.27-29 However, due to tumor molecular heterogeneity, only
siRNA-based down-regulation of a single oncogenic target (EGFRvIII) may not be
efficacious. Histone deacetylase (HDAC) inhibitors like suberoylanilide hydroxamic acid
(SAHA) and EGFR tyrosine kinase inhibitors like erlotinib have been reported to enhance
the efficacy of other EGFR antagonists.26, 30 To this end, we used either SAHA or erlotinib
for co-delivery with siRNA against EGFRvIII oncogene to deactivate the target signaling
pathway in a selective and efficient manner. These drugs have already shown some
promising results for GBM therapy, but have met with limited success since they require
higher doses and longer exposures, which may lead to increased toxic side-effects.31
Our hypothesis is that combination of anti-cancer drugs against complementary therapeutic
targets with siRNA therapeutics against EGFRvIII would have a cooperative effect on
induction of apoptosis in brain tumor cells. To test this hypothesis, we initially compared the
anti-proliferative capability of anti-cancer drugs (SAHA and Erlotinib) and siRNA against
EGFRvIII in glioblastoma cells, either individually or in combination by using cell viability
assay (Figure 2b). From the data, we could clearly observe a cooperative inhibition of
glioblastoma cell proliferation when SAHA (5 μM )was co-delivered with the siRNA (200
nM; polymer concentration 100 μM), as compared to treating the cells with only SAHA at
the same concentration (5 μM). This can be attributed to the fact that SAHA is known to
significantly enhance the efficacy of agents targeting EGFR signaling pathway by
modulating several indirect downstream targets, which in turn are key regulators of EGFR
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pathways. Similarly, co-delivery of erlotinib (30 μM) and siRNA (200 nM) also inhibited
tumor cell proliferation to a higher extent (Figure 2b). Additionally, we also monitored the
effect of co-delivery of both siRNA and anticancer drugs on inducing cell death in
glioblastoma cells using the apoptosis assay (Annexin-V/Propidium Iodide assay).
Significantly higher proportion of cell population treated with both siRNA and SAHA were
Annexin-V-FITC-positive as compared to the individual treatments as well as untreated
cells. These results indicate greater induction of apoptosis in cells treated with both siRNA
and SAHA, as compared to those with only SAHA and only siRNA treatment (Figure 2c). A
similar trend in the cooperative induction of apoptosis was seen in case of combined
erlotinib/siRNA treatment (Figure 2c). We also found that complexation of SAHA and
erlotinib within the CD cavity improved their aqueous solubility and hence increased their
potency, measured as IC50 values, by approximately 2-fold as compared to its DMSO
solution (see Figure S6 in the supporting information). Thus, these results show the
cooperative effect on selective inducing the apoptosis of brain tumor cells by the right
combination of siRNA and anti-cancer drugs and the capability of our delivery molecules
(DexAMs) for target-specific delivery and improved chemotherapeutic efficacy.
In conclusion, we synthesized a multimodal delivery platform to simultaneously deliver two
orthogonal therapeutic modalities having cooperative therapeutic efficacy in an efficient and
selective manner to the target brain tumor cells. As a proof of concept experiment, we
demonstrated that target-specific co-delivery of siRNA and anti-cancer drugs having
complementary therapeutic results would be a novel method to enhance the apoptotic
signaling pathways and inhibit the proliferation signaling pathways in brain tumor cells.
Potentially, our approach and methodology can be beneficial for introducing exogenous
siRNA combined with small molecules into other mammalian cells, which can represent a
powerful approach for the optimal manipulating signal transduction. Our synthetic
techniques afforded facile manipulation of the polymer structure to achieve efficient
transfection with minimal polymer-mediated cytotoxicity. The strategy of co-delivering anti-
cancer drug with therapeutic siRNA is particularly advantageous for in vivo applications, so
that both the moieties are delivered to the target cells using a single delivery platform. Our
versatile delivery platform can also be used to co-deliver different kinds of small molecules
and nucleic acids to regulate cancer cell fate such as proliferation, migration and apoptosis
by targeting multiple signaling pathways. Collectively, our DexAM-based co-delivery
strategy has significant potential for cancer therapy as well as regulating cell fate by
modulating key signaling cascades.
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Scheme 1.
(A) General scheme showing co-delivery of small molecules like anticancer drugs and
siRNA to cancer cells using cyclodextrin modified polyamines (DeXAMs). (B) Chemical
structure of the delivery vehicle. (See supporting information for other DexAM generations)
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Scheme 2.
(A) Schematic representation of synthesis of DexAMs. (B) Conjugation of drugs and
antibodies to DexAMs
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Figure 1.
Cytotoxicity and transfection efficiency of DexAM-4 (D4). (A)Effect of cyclodextrin
grafting on polymer-mediated toxicity. (B) Comparison of toxicities of DexAM-4 with
commercially used transfection agents at optimized concentrations of delivery agent and
siRNA. (LF 2000 -Lipofectamine 2000 and Xgene - Xtremegene). (C) Phase contrast
(C1,C2) and fluorescent (C3,C4) images showing siRNA-mediated decrease in green
fluorescence in treated and control (untreated) U87-EGFP cells.
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Figure 2.
Targeted delivery of DexAMs and cooperative effect of anticancer drugs and siRNA on
glioblastoma cells.(A) Targeted delivery of DexAMs modified with EGFR antibodies in
highly-tumorigenic U87-EGFP cells and less-tumorigenic PC-12 cells. (B) Viability of
glioblastoma cells following individual treatments and co-delivery of drugs and siRNA,
based upon MTS assay.(C) Flow cytometry based Annexin-V/PI assay demonstrating the
apoptotic effect of combined and individual siRNA and drug treatments. Percentages
represent Annexin-V-positive (apoptotic cells). For all experiments, the polymer
concentration was kept constant (100 μM), wherease the concentrations of SAHA, Erlotinib
and siRNA were 5 μM, 30 μM and 200 nM respectively.
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